Overview

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca